• Vaccine Name: recombinant Brucella Omp31 antigen vaccine
• Target Pathogen: Brucella spp.
• Target Disease: Brucellosis
• Vaccine Ontology ID: VO_0009312
• Type: Subunit vaccine
• Status: Research
• Host Species for Licensed Use: Dog
• Host Species as Laboratory Animal Model: Mus musculus (BALB/c mice)
• Antigen: Omp31
• Adjuvant: incomplete Freund adjuvant; aluminum hydroxide; Quil A; Montanide IMS 3012 VGPR
• Preparation: Recombinant Omp31 antigen formulated with various adjuvants (incomplete Freund adjuvant, aluminum hydroxide, Quil A, Montanide IMS 3012 VGPR); plasmid pCIOmp31 DNA vaccine; and a prime-boost strategy with pCIOmp31 plasmid followed by recombinant Omp31 protein boost. (Clausse et al, 2014)
• Description: Canine brucellosis caused by Brucella canis currently lacks a vaccine; this study evaluates Omp31 as a candidate antigen for vaccine development. Efficacy: Recombinant Omp31 with different adjuvants and the prime-boost strategy conferred protection against B. canis infection in mice. Immune response: Strong IgG antibody response induced; spleen cells from recombinant Omp31-immunized mice produced gamma interferon and IL-4, indicating a mixed Th1-Th2 immune response. (Clausse et al, 2014)

Mouse Response

• Host Strain: BALB/c
• Immune Response: Strong IgG antibody response induced; spleen cells from recombinant Omp31-immunized mice produced gamma interferon and IL-4, indicating a mixed Th1-Th2 immune response. (Clausse et al, 2014)
• Challenge Protocol: BALB/c mice were subcutaneously immunized with the different vaccine formulations; immune responses were measured by IgG production and cytokine secretion (gamma interferon and IL-4) from spleen cells after in vitro stimulation; protective efficacy was assessed by challenge with B. canis. (Clausse et al, 2014)
• Efficacy: Recombinant Omp31 with different adjuvants and the prime-boost strategy conferred protection against B. canis infection in mice. (Clausse et al, 2014)
• Description: BALB/c mice were subcutaneously immunized with the different vaccine formulations; immune responses were measured by IgG production and cytokine secretion (gamma interferon and IL-4) from spleen cells after in vitro stimulation; protective efficacy was assessed by challenge with B. canis. (Clausse et al, 2014)